Search
Search
Kristin Barnes, OD; Neda Shamie, MD; and Arjan Hura, MD
Show Description +
Kristin Barnes, OD; Neda Shamie, MD; and Arjan Hura, MD, explain how XDEMVY® (by Tarsus Pharmaceuticals) has changed their approaches to patient care for patients with Demodex blepharitis. They also review the process for implementing this treatment into practice and getting buy-in from patients. Real doctors. Paid testimonials. XDEMVY® for DB is available by prescription only. Results may vary.
Posted: 8/12/2025
Kristin Barnes, OD; Neda Shamie, MD; and Arjan Hura, MD
Kristin Barnes, OD; Neda Shamie, MD; and Arjan Hura, MD, explain how XDEMVY® (by Tarsus Pharmaceuticals) has changed their approaches to patient care for patients with Demodex blepharitis. They also review the process for implementing this treatment into practice and getting buy-in from patients. Real doctors. Paid testimonials. XDEMVY® for DB is available by prescription only. Results may vary.
Posted: 8/12/2025
For XDEMVY access support, contact Tarsus Connect by calling 1-866-846-3092
HIPAA Authorization
Enrollment Form for the Patient Assistance Program
Sample Letter of Appeal
Sample Letter of Medical Necessity
Prior Authorization Checklist
Pharmacy Fax Rx Form
Getting Started Guide
About XDEMVY
Demodex blepharitis affects ~58% of eye care patients in the US - that’s approximately 25 million patients.3,4 XDEMVY is designed to effectively and safely target, paralyze, and kill Demodex mites in patients with Demodex blepharitis.1
Visit us online: xdemvyhcp.com
Follow XDEMVY
SHOW MORE
XDEMVY is indicated for the treatment of Demodex blepharitis.
Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.
ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
© 2023 Tarsus Pharmaceuticals, Inc.
US--2300625
INDICATIONS AND USAGE
XDEMVY is indicated for the treatment of Demodex blepharitis.
Important Safety Information:
WARNINGS AND PRECAUTIONS
Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.
ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Please see full Prescribing Information.
1. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.
2. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094.
3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164.
4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987.
_1709044279.jpg?auto=compress,format&w=180)
